Polychromatic flow cytometry in the clinical laboratory

Summary Technological advances in flow cytometry include increasingly sophisticated instruments and an expanding range of fluorochromes. These advances are making it possible to detect an increasing number of markers on a single cell. The term polychromatic flow cytometry applies to such systems that detect five or more markers simultaneously. This review provides an overview of the current and future impact of polychromatic flow cytometry in the clinical laboratory. The use of multiple markers has several advantages in the diagnosis and monitoring of haematological malignancies. Cell populations can be analysed more comprehensively and efficiently, and abnormal populations can be distinguished more readily when normal counterparts are present. Polychromatic flow cytometry is particularly useful in the evaluation of plasma cells, and the role of flow cytometry in the assessment of plasma cell disorders is reviewed in depth. There is improved sensitivity in the assessment of small populations, which is critical in the evaluation of minimal residual disease. Flow cytometry can also play a role in assessment of circulating tumour cells in carcinoma. Introduction of polychromatic flow cytometry is a complex process with many challenges including design of antibody panels and instrument compensation. Developments in data analysis are required to realise the full benefits of the other technical advances. Standardisation of protocols may reduce inter-laboratory variation. While the complexity of polychromatic flow cytometry creates challenges, it has substantial potential to improve clinical analysis.

[1]  Mario Roederer,et al.  A chromatic explosion: the development and future of multiparameter flow cytometry , 2008, Immunology.

[2]  Mario Roederer,et al.  Quality assurance for polychromatic flow cytometry , 2006, Nature Protocols.

[3]  J. Dongen,et al.  Clinical significance of flowcytometric minimal residual disease detection in pediatric acute myeloid leukemia patients treated according to the DCOG ANLL97/MRC AML12 protocol , 2010, Leukemia.

[4]  K. Foon,et al.  Recent advances in flow cytometry: application to the diagnosis of hematologic malignancy. , 1997, Blood.

[5]  H. Nückel,et al.  Detection of malignant haematopoietic cells in the cerebrospinal fluid by conventional cytology and flow cytometry. , 2006, Clinical and laboratory haematology.

[6]  E S Costa,et al.  A probabilistic approach for the evaluation of minimal residual disease by multiparameter flow cytometry in leukemic B‐cell chronic lymphoproliferative disorders , 2008, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

[7]  M. Borowitz,et al.  Immunophenotyping of acute leukemia by flow cytometric analysis. Use of CD45 and right-angle light scatter to gate on leukemic blasts in three-color analysis. , 1993, American journal of clinical pathology.

[8]  Mario Roederer,et al.  Compensation in Flow Cytometry , 2002, Current protocols in cytometry.

[9]  Improved compensation in flow cytometry by multivariable optimization , 2011, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

[10]  D. Nixon,et al.  Nine‐color flow cytometry for accurate measurement of T cell subsets and cytokine responses. Part I: Panel design by an empiric approach , 2008, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

[11]  A. Órfão,et al.  Risk of progression in smouldering myeloma and monoclonal gammopathies of unknown significance: comparative analysis of the evolution of monoclonal component and multiparameter flow cytometry of bone marrow plasma cells , 2010, British journal of haematology.

[12]  D. Campana,et al.  Comparative analysis of flow cytometry and polymerase chain reaction for the detection of minimal residual disease in childhood acute lymphoblastic leukemia , 2004, Leukemia.

[13]  F. Preffer,et al.  Advances in complex multiparameter flow cytometry technology: Applications in stem cell research , 2009, Cytometry. Part B, Clinical cytometry.

[14]  M. Raffeld,et al.  Flow cytometric immunophenotypic assessment of T-cell clonality by Vβ repertoire analysis: detection of T-cell clonality at diagnosis and monitoring of minimal residual disease following therapy. , 2011, American journal of clinical pathology.

[15]  Kenneth C. Anderson,et al.  Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group , 2003, British journal of haematology.

[16]  B. Geiger,et al.  Diverse niches within multiple myeloma bone marrow aspirates affect plasma cell enumeration , 2006, British journal of haematology.

[17]  Robert A Kyle,et al.  Circulating plasma cells detected by flow cytometry as a predictor of survival in 302 patients with newly diagnosed multiple myeloma. , 2005, Blood.

[18]  F. Behm,et al.  Prognostic importance of measuring early clearance of leukemic cells by flow cytometry in childhood acute lymphoblastic leukemia. , 2002, Blood.

[19]  Karel Drbal,et al.  CD molecules 2005: human cell differentiation molecules. , 2005, Blood.

[20]  B. Wood,et al.  Immunophenotyping of Leukemia and Lymphoma by Flow Cytometry , 2006 .

[21]  Normal lymphocytes from leukemic samples as an internal quality control for fluorescence intensity in immunophenotyping of acute leukemias , 2006, Cytometry. Part B, Clinical cytometry.

[22]  Bruce Greig,et al.  2006 Bethesda International Consensus recommendations on the immunophenotypic analysis of hematolymphoid neoplasia by flow cytometry: Optimal reagents and reporting for the flow cytometric diagnosis of hematopoietic neoplasia , 2007, Cytometry. Part B, Clinical cytometry.

[23]  Holden T Maecker,et al.  Flow cytometry controls, instrument setup, and the determination of positivity , 2006, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

[24]  Philip S Low,et al.  In vivo quantitation of rare circulating tumor cells by multiphoton intravital flow cytometry , 2007, Proceedings of the National Academy of Sciences.

[25]  M. Bøgsted,et al.  Multiparametric flow cytometry profiling of neoplastic plasma cells in multiple myeloma , 2010, Cytometry. Part B, Clinical cytometry.

[26]  Ruud H. Brakenhoff,et al.  Detection, clinical relevance and specific biological properties of disseminating tumour cells , 2008, Nature Reviews Cancer.

[27]  G. Morgan,et al.  Circulating plasma cells in multiple myeloma: characterization and correlation with disease stage , 1997, British journal of haematology.

[28]  W. Erber,et al.  Immunophenotyping of lymphoproliferative disorders: state of the art , 2005, Pathology.

[29]  M. Terol,et al.  Prognostic value of immunophenotyping in multiple myeloma: a study by the PETHEMA/GEM cooperative study groups on patients uniformly treated with high-dose therapy. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  N. Davidson,et al.  Detection and viability of tumor cells in peripheral blood stem cell collections from breast cancer patients using immunocytochemical and clonogenic assay techniques. , 1993, Blood.

[31]  R. Bataille,et al.  The phenotype of normal, reactive and malignant plasma cells. Identification of "many and multiple myelomas" and of new targets for myeloma therapy. , 2006, Haematologica.

[32]  G. Morgan,et al.  Flow cytometric disease monitoring in multiple myeloma: the relationship between normal and neoplastic plasma cells predicts outcome after transplantation. , 2002, Blood.

[33]  R. Gelman,et al.  Use of CD45 gating in three and four-color flow cytometric immunophenotyping: guideline from the National Institute of Allergy and Infectious Diseases, Division of AIDS. , 2002, Cytometry.

[34]  N. Kröger,et al.  Specificity of reverse transcriptase polymerase chain reaction assays designed for the detection of circulating cancer cells is influenced by cytokines in vivo and in vitro. , 1998, British Journal of Cancer.

[35]  G. Morgan,et al.  Quantitation of minimal disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay improves the prediction of outcome and can be used to optimize therapy. , 2001, Blood.

[36]  L. Medeiros,et al.  TCR-Vβ flow cytometric analysis of peripheral blood for assessing clonality and disease burden in patients with T cell large granular lymphocyte leukaemia , 2010, Journal of Clinical Pathology.

[37]  M. O'gorman,et al.  CD4 T cell measurements in the management of antiretroviral therapy—A review with an emphasis on pediatric HIV‐infected patients , 2008, Cytometry. Part B, Clinical cytometry.

[38]  Nada Jabado,et al.  New technologies for the detection of circulating tumour cells. , 2010, British medical bulletin.

[39]  J. Katzmann,et al.  Flow cytometric assessment of TCR-Vbeta expression in the evaluation of peripheral blood involvement by T-cell lymphoproliferative disorders: a comparison with conventional T-cell immunophenotyping and molecular genetic techniques. , 2004, American journal of clinical pathology.

[40]  W. V. van Wieringen,et al.  Flow cytometric lymphocyte subset enumeration: 10 years of external quality assessment in the Benelux countries , 2008, Cytometry. Part B, Clinical cytometry.

[41]  D. Dorfman,et al.  Single tube, six-color flow cytometric analysis is a sensitive and cost-effective technique for assaying clonal plasma cells. , 2010, American Journal of Clinical Pathology.

[42]  M. Keeney,et al.  Circulating Tumor Cell Analysis: Technical and Statistical Considerations for Application to the Clinic , 2009, Journal of oncology.

[43]  A. Berner,et al.  Detection of malignant epithelial cells in effusions using flow cytometric immunophenotyping: an analysis of 92 cases. , 2002, American journal of clinical pathology.

[44]  A. Hagenbeek,et al.  Detection of Minimal Residual Disease in Acute Leukemia by Flow Cytometry a , 1986, Annals of the New York Academy of Sciences.

[45]  D. Dingli,et al.  Flow cytometric detection of circulating myeloma cells before transplantation in patients with multiple myeloma: a simple risk stratification system. , 2005, Blood.

[46]  H. Döhner,et al.  Standardized MRD flow and ASO IGH RQ-PCR for MRD quantification in CLL patients after rituximab-containing immunochemotherapy: a comparative analysis , 2009, Leukemia.

[47]  G. Tricot,et al.  Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma. , 2004, American journal of clinical pathology.

[48]  B. Wood,et al.  Ten‐Color Immunophenotyping of Hematopoietic Cells , 2005, Current protocols in cytometry.

[49]  Elaine Coustan-Smith,et al.  Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial. , 2010, The Lancet. Oncology.

[50]  J. Byrd,et al.  International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia , 2007, Leukemia.

[51]  R. Arceci,et al.  Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study , 2009 .

[52]  E S Costa,et al.  Automated pattern-guided principal component analysis vs expert-based immunophenotypic classification of B-cell chronic lymphoproliferative disorders: a step forward in the standardization of clinical immunophenotyping , 2010, Leukemia.

[53]  J. Gratama,et al.  Flow cytometric characterization of cerebrospinal fluid cells , 2011, Cytometry. Part B, Clinical cytometry.

[54]  Marina Ruggeri,et al.  Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders , 2008, Haematologica.

[55]  J. Katzmann,et al.  Flow Cytometric Assessment of TCR-Vβ Expression in the Evaluation of Peripheral Blood Involvement by T-Cell Lymphoproliferative Disorders , 2004 .

[56]  A. Órfão,et al.  Comparison of immunofixation, serum free light chain, and immunophenotyping for response evaluation and prognostication in multiple myeloma. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[57]  A Orfao,et al.  2006 Bethesda International Consensus recommendations on the flow cytometric immunophenotypic analysis of hematolymphoid neoplasia: Medical indications , 2007, Cytometry. Part B, Clinical cytometry.

[58]  R. Braylan,et al.  CD10 expression in follicular lymphoma and large cell lymphoma is different from that of reactive lymph node follicles. , 1998, Archives of pathology & laboratory medicine.

[59]  A. Órfão,et al.  High‐sensitive immunophenotyping and DNA ploidy studies for the investigation of minimal residual disease in multiple myeloma , 1999, British journal of haematology.

[60]  M. Roederer,et al.  Data analysis in flow cytometry: The future just started , 2010, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

[61]  F. Craig,et al.  Flow cytometric immunophenotyping for hematologic neoplasms. , 2008, Blood.

[62]  A. Órfão,et al.  New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells. , 2007, Blood.

[63]  N. Nadal,et al.  Multiparametric analysis of normal and postchemotherapy bone marrow: Implication for the detection of leukemia‐associated immunophenotypes , 2008, Cytometry. Part B, Clinical cytometry.

[64]  P. Vyas,et al.  Assessment of minimal residual disease in acute myeloid leukemia , 2010, Current opinion in oncology.

[65]  Hannes Stockinger,et al.  CD molecules 2006--human cell differentiation molecules. , 2007, Journal of immunological methods.

[66]  R. Pieters,et al.  Standardized MRD quantification in European ALL trials: Proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18–20 September 2008 , 2010, Leukemia.

[67]  Dieter Falkenhagen,et al.  Enrichment of circulating tumor cells from a large blood volume using leukapheresis and elutriation: Proof of concept , 2011, Cytometry. Part B, Clinical cytometry.

[68]  Torsten Haferlach,et al.  The role of multiparameter flow cytometry for disease monitoring in AML. , 2010, Best practice & research. Clinical haematology.

[69]  S. Perkins,et al.  Quantitation of plasma cells in bone marrow aspirates by flow cytometric analysis compared with morphologic assessment. , 2007, Archives of pathology & laboratory medicine.

[70]  Tomáš Kalina,et al.  Profiling of polychromatic flow cytometry data on B‐cells reveals patients' clusters in common variable immunodeficiency , 2009, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

[71]  John W M Martens,et al.  Circulating tumour cell detection on its way to routine diagnostic implementation? , 2007, European journal of cancer.

[72]  M. Stetler-Stevenson,et al.  Role of flow cytometry of peripheral blood and bone marrow aspirates in early myeloma. , 2011, Seminars in hematology.

[73]  U. Johansson,et al.  Pitfalls in the use of multicolour flow cytometry in haematology , 2011, Journal of Clinical Pathology.

[74]  B. Schäfer,et al.  Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia , 2008, Leukemia.

[75]  A. Teigler‐Schlegel,et al.  Immunophenotypic differences between diagnosis and relapse in childhood AML: Implications for MRD monitoring , 2005, Cytometry. Part B, Clinical cytometry.

[76]  Kazuo Takeda,et al.  Enumeration, characterization, and collection of intact circulating tumor cells by cross contamination‐free flow cytometry , 2011, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

[77]  Wolfgang Kern,et al.  Standardization of flow cytometry in myelodysplastic syndromes: report from the first European LeukemiaNet working conference on flow cytometry in myelodysplastic syndromes , 2009, Haematologica.

[78]  P. Chattopadhyay,et al.  Seventeen-colour flow cytometry: unravelling the immune system , 2004, Nature Reviews Immunology.

[79]  G. Basso,et al.  Drug-induced immunophenotypic modulation in childhood ALL: implications for minimal residual disease detection , 2005, Leukemia.

[80]  H. Asaoku,et al.  Phenotypic difference of normal plasma cells from mature myeloma cells. , 1993, Blood.

[81]  B. Wood,et al.  2006 Bethesda International Consensus recommendations on the immunophenotypic analysis of hematolymphoid neoplasia by flow cytometry: Recommendations for training and education to perform clinical flow cytometry , 2007, Cytometry. Part B, Clinical cytometry.

[82]  Dario Campana,et al.  Role of minimal residual disease monitoring in adult and pediatric acute lymphoblastic leukemia. , 2009, Hematology/oncology clinics of North America.

[83]  A. Porwit,et al.  CD34+ cell subpopulations detected by 8-color flow cytometry in bone marrow and in peripheral blood stem cell collections: application for MRD detection in leukemia patients , 2009, International journal of hematology.

[84]  M. Plummer,et al.  International agency for research on cancer. , 2020, Archives of pathology.

[85]  G. Sauter,et al.  Changes in Cytoskeletal Protein Composition Indicative of an Epithelial-Mesenchymal Transition in Human Micrometastatic and Primary Breast Carcinoma Cells , 2005, Clinical Cancer Research.

[86]  David Gillis,et al.  The role of multiparameter flow cytometry for detection of minimal residual disease in acute myeloid leukemia. , 2009, American journal of clinical pathology.

[87]  A. Órfão,et al.  Evaluation of multiparameter flow cytometry for the detection of breast cancer tumor cells in blood samples. , 2005, American journal of clinical pathology.

[88]  J. V. van Dongen,et al.  Molecular and flow cytometric analysis of the Vbeta repertoire for clonality assessment in mature TCRalphabeta T-cell proliferations. , 2001, Blood.

[89]  Jennings Cd,et al.  Recent Advances in Flow Cytometry: Application to the Diagnosis of Hematologic Malignancy , 1997 .

[90]  B. Wood,et al.  9-color and 10-color flow cytometry in the clinical laboratory. , 2006, Archives of pathology & laboratory medicine.

[91]  M. Roederer,et al.  Optimizing a multicolor immunophenotyping assay. , 2007, Clinics in laboratory medicine.

[92]  F. Preffer,et al.  Flow cytometry and the stability of phycoerythrin‐tandem dye conjugates , 2009, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

[93]  Anne A. Hurley,et al.  Quality Control in Phenotypic Analysis by Flow Cytometry , 1997, Current protocols in cytometry.

[94]  M. Ward,et al.  The use of flow cytometry in the diagnosis and monitoring of malignant hematological disorders. , 1999, Pathology.

[95]  S. Rajkumar,et al.  Anti‐CD20 monoclonal antibody therapy in multiple myeloma , 2008, British journal of haematology.